Pinostilbene: A Novel Androgen Receptor Inhibitor for Prostate Cancer Treatment and Enzalutamide Resistance
Discover the groundbreaking research on Pinostilbene's potent anti-cancer properties, offering new hope for treating advanced prostate cancer and overcoming resistance to existing therapies.
Get a Quote & SampleProduct Core Value

Pinostilbene
Pinostilbene, a derivative of resveratrol, stands out as a promising therapeutic agent in the fight against prostate cancer. Its unique ability to inhibit the androgen receptor (AR) pathway, a key driver of prostate cancer growth, makes it a valuable compound. As a reliable supplier in China, we offer high-purity Pinostilbene for your research and development needs, supporting advancements in targeted cancer therapies.
- Pinostilbene prostate cancer treatment demonstrates significant potential in clinical applications, offering a novel approach to patient care.
- The mechanism of Pinostilbene androgen receptor inhibitor action involves direct binding to the AR, blocking its activation and downstream signaling.
- Addressing Pinostilbene enzalutamide resistance, this compound shows efficacy against cancer cells that have become resistant to standard treatments.
- Research into Pinostilbene ARv7 inhibition highlights its capability to target specific AR variants, a critical step in treating aggressive forms of prostate cancer.
Advantages Offered
Targeted AR Inhibition
Pinostilbene effectively targets the androgen receptor pathway, a critical factor in prostate cancer progression, making it a key component in developing effective cancer therapy research.
Overcoming Treatment Resistance
Its efficacy against enzalutamide-resistant cancer cells positions Pinostilbene as a vital solution for patients who have developed resistance to current therapies, a crucial aspect of cancer drug resistance mechanisms.
Broad Efficacy Range
With its ability to inhibit both full-length AR and AR variants like ARv7, Pinostilbene offers a broad spectrum of action, supporting its role in targeted cancer therapies.
Key Applications
Prostate Cancer Treatment
Pinostilbene is a promising candidate for developing new treatments for prostate cancer, addressing both early-stage and advanced, resistant forms. Utilizing insights from natural compounds in oncology research is key.
Androgen Receptor Modulation
The compound's primary mechanism of action involves modulating the androgen receptor pathway, a central target in understanding androgen receptor signaling.
Combating CRPC
For Castration-Resistant Prostate Cancer (CRPC), Pinostilbene offers a new therapeutic avenue, particularly for cases resistant to enzalutamide. This aligns with advancements in molecular oncology research.
Drug Resistance Research
Studying Pinostilbene provides valuable insights into overcoming drug resistance in cancer, contributing to broader knowledge in cancer drug resistance mechanisms.